Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13(10), 714–726 (2013).•• Comprehensive review dealing with the evolving paradigm of cancer drug resistance.
  Medline CASGoogle Scholar
• 2 Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5(4), 275–284 (2005).
  Medline CASGoogle Scholar
• 3 Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 14(3), 150–163 (2011).•• Excellent review elucidating nanomedicine that overcomes cancer drug resistance.
  Medline CASGoogle Scholar
• 4 Gao J, Feng SS, Guo Y. Nanomedicine for treatment of cancer stem cells. Nanomedicine (Lond.) 9(2), 181–184 (2014).
  CASGoogle Scholar
• 5 Stover TC, Kim YS, Lowe TL, Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29(3), 359–369 (2008).
  Medline CASGoogle Scholar
• 6 Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers doxorubicin resistance in human breast cancer cells. J. Biol. Chem. 274(2), 1140–1146 (1999).
  Medline CASGoogle Scholar
• 7 Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 271(32), 19530–19536 (1996).
  Medline CASGoogle Scholar
• 8 Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int. J. Oncol. 15(3), 541–546 (1999).
  Medline CASGoogle Scholar
• 9 Rath G, Schneider C, Langlois B et al. De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int. J. Biochem. Cell Biol. 41(5), 1165–1172 (2009).
  Medline CASGoogle Scholar
• 10 Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12(8), 1533–1541 (2007).
  Medline CASGoogle Scholar
• 11 Liu YY, Yu JY, Yin D et al. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 22(7), 2541–2551 (2008).• Investigating the role of ceramide in driving cancer resistance.
  Medline CASGoogle Scholar
• 12 van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 67(10), 4843–4850 (2007).•• Utilizing nanoparticles to deliver ceramide to cells to overcome cancer resistance.
  Medline CASGoogle Scholar
• 13 Gouazé V, Yu JY, Bleicher RJ et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 3(5), 633–639 (2004).
  Medline CASGoogle Scholar
• 14 Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15(3), 719–730 (2001).
  Medline CASGoogle Scholar
• 15 van Lummel M, van Blitterswijk WJ, Vink SR et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J. 25(1), 280–289 (2011).
  Medline CASGoogle Scholar
• 16 Veldman RJ, Koning GA, van Hell A et al. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J. Pharmacol. Exp. Ther. 315(2), 704–710 (2005).
  Medline CASGoogle Scholar
• 17 Pedrosa LR, van Hell A, Süss R et al. Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids. Pharm. Res. 30(7), 1883–1895 (2013).
  Medline CASGoogle Scholar
• 18 Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism – a strategy for overcoming drug resistance. J. Natl Cancer Inst. 93(5), 347–357 (2001).
  Medline CASGoogle Scholar
• 19 Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 14(10), 3193–3203 (2008).
  Medline CASGoogle Scholar
• 20 Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer 121(8), 1830–1838 (2007).•• Co-delivery of chemotherapy drug and ceramide to overcome cancer resistance.
  Medline CASGoogle Scholar
• 21 Fonseca NA, Gomes-da-Silva LC, Moura V, Simões S, Moreira JN. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. J. Control. Release 196, 122–131 (2014).
  Medline CASGoogle Scholar
• 22 Abraham SA, McKenzie C, Masin D et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and ph gradient loading. Clin. Cancer Res. 10(2), 728–738 (2004).
  Medline CASGoogle Scholar
• 23 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145–160 (2005).
  Medline CASGoogle Scholar
• 24 Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(15), 2713–2722 (2005).
  Medline CASGoogle Scholar
• 25 Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. Size-dependent endocytosis of nanoparticles. Adv. Mater. 21, 419–424 (2009).
  MedlineGoogle Scholar
• 26 Decuzzi P, Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 28(18), 2915–2922 (2007).
  Medline CASGoogle Scholar
• 27 Veiga MP, Arrondo JL, Goñi FM, Alonso A. Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. Biophys. J. 76(1), 342–350 (1999).
  Medline CASGoogle Scholar
• 28 Khazanov E, Priev A, Shillemans JP, Barenholz Y. Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application. Langmuir 24(13), 6965–6980 (2008).•• Elucidating how to use surfactant to stabilize ceramide in liposomes.
  Medline CASGoogle Scholar
• 29 Han L, Miyasaka K, Terasaki O, Che S. Evolution of packing parameters in the structural changes of silica mesoporous crystals: cage-type, 2D cylindrical, bicontinuous diamond and gyroid, and lamellar. J. Am. Chem. Soc. 133(30), 11524–11533 (2011).
  Medline CASGoogle Scholar
• 30 Kumar VV. Complementary molecular shapes and additivity of the packing parameter of lipids. Proc. Natl Acad. Sci. USA 88(2), 444–448 (1991).
  Medline CASGoogle Scholar
• 31 Wheeler JJ, Palmer L, Ossanlou M et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6(2), 271–281 (1999).
  Medline CASGoogle Scholar
• 32 Zhang YP, Sekirov L, Saravolac EG et al. Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther. 6(8), 1438–1447 (1999).
  Medline CASGoogle Scholar
• 33 Feng SS. Interpretation of mechanochemical properties of lipid monolayers at the air-water or oil-water interface and bilayer vesicles from equation of state or pressure-area measurement. Langmuir 15(4), 998–1010 (1999).
  CASGoogle Scholar
• 34 Feng SS, MacDonald RC. Effects of chain unsaturation on equation of state for monolayers at the air-water interface. Biophys. J. 69(2), 460–469 (1995).
  Medline CASGoogle Scholar
• 35 Cao N, Feng SS. Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): in vitro cytotoxicity, in vivo pharmacokinetics and biodistribution. Biomaterials 29(28), 3856–3865 (2008).
  Medline CASGoogle Scholar
• 36 Anbharasi V, Cao N, Feng SS. Targeted delivery of doxorubicin conjugated to folic acid and d-α-tocopheryl polyethylene glycol succinate (TPGS). J. Biomed. Mat. Res. A 94(3), 730–743 (2010).
  MedlineGoogle Scholar
• 37 Gao J, Xia Y, Chen H et al. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond.) 9(2), 279–293 (2014).
  CASGoogle Scholar
• 38 Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2(4), 369–381 (2005).
  Medline CASGoogle Scholar
• 39 Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res. 10(7), 2530–2537 (2004).
  Medline CASGoogle Scholar
• 40 Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104(1), 10–14 (1980).
  Medline CASGoogle Scholar
• 41 Gao J, Feng SS, Guo Y. Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine (Lond.) 7(4), 465–468 (2012).•• Excellent editorial elucidating the advantages of nanomedicine in overcoming cancer resistance.
  CASGoogle Scholar
• 42 Lasic DD, Woodle MC, Martin FJ, Valentincic T. Phase behavior of ‘stealth-lipid’ decithin mixtures. Period Biol. 93, 9287–9290 (1991).
  Google Scholar
• 43 Watters RJ, Kester M, Tran MA, Loughran TP Jr, Liu X. Development and use of ceramide nanoliposomes in cancer. Methods Enzymol. 508, 89–108 (2012).
  Medline CASGoogle Scholar